These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

947 related articles for article (PubMed ID: 28662101)

  • 1. Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer.
    De Marco C; Laudanna C; Rinaldo N; Oliveira DM; Ravo M; Weisz A; Ceccarelli M; Caira E; Rizzuto A; Zoppoli P; Malanga D; Viglietto G
    PLoS One; 2017; 12(6):e0178865. PubMed ID: 28662101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of miRNA profiles identified miR-196a as a crucial mediator of aberrant PI3K/AKT signaling in lung cancer cells.
    Guerriero I; D'Angelo D; Pallante P; Santos M; Scrima M; Malanga D; De Marco C; Ravo M; Weisz A; Laudanna C; Ceccarelli M; Falco G; Rizzuto A; Viglietto G
    Oncotarget; 2017 Mar; 8(12):19172-19191. PubMed ID: 27880728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase.
    Scrima M; De Marco C; Fabiani F; Franco R; Pirozzi G; Rocco G; Ravo M; Weisz A; Zoppoli P; Ceccarelli M; Botti G; Malanga D; Viglietto G
    PLoS One; 2012; 7(2):e30427. PubMed ID: 22363436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
    Lu C; Shan Z; Hong J; Yang L
    Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells.
    Higgins MJ; Beaver JA; Wong HY; Gustin JP; Lauring JD; Garay JP; Konishi H; Mohseni M; Wang GM; Cidado J; Jelovac D; Cosgrove DP; Tamaki A; Abukhdeir AM; Park BH
    Cancer Biol Ther; 2011 Feb; 11(3):358-67. PubMed ID: 21124076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer.
    Shih MC; Chen JY; Wu YC; Jan YH; Yang BM; Lu PJ; Cheng HC; Huang MS; Yang CJ; Hsiao M; Lai JM
    Oncogene; 2012 May; 31(19):2389-400. PubMed ID: 21996732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA.
    Kim JS; Lee C; Bonifant CL; Ressom H; Waldman T
    Mol Cell Biol; 2007 Jan; 27(2):662-77. PubMed ID: 17060456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness.
    Tserga A; Chatziandreou I; Michalopoulos NV; Patsouris E; Saetta AA
    Virchows Arch; 2016 Jul; 469(1):35-43. PubMed ID: 27059323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disruption of epithelial architecture caused by loss of PTEN or by oncogenic mutant p110α/PIK3CA but not by HER2 or mutant AKT1.
    Berglund FM; Weerasinghe NR; Davidson L; Lim JC; Eickholt BJ; Leslie NR
    Oncogene; 2013 Sep; 32(37):4417-26. PubMed ID: 23085752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Akt1/IL-6/STAT3 pathway regulates growth of lung tumor initiating cells.
    Malanga D; De Marco C; Guerriero I; Colelli F; Rinaldo N; Scrima M; Mirante T; De Vitis C; Zoppoli P; Ceccarelli M; Riccardi M; Ravo M; Weisz A; Federico A; Franco R; Rocco G; Mancini R; Rizzuto A; Gulletta E; Ciliberto G; Viglietto G
    Oncotarget; 2015 Dec; 6(40):42667-86. PubMed ID: 26486080
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Lu XX; Cao LY; Chen X; Xiao J; Zou Y; Chen Q
    Biomed Res Int; 2016; 2016():2476842. PubMed ID: 27822469
    [No Abstract]   [Full Text] [Related]  

  • 14. The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas.
    Shoji K; Oda K; Nakagawa S; Hosokawa S; Nagae G; Uehara Y; Sone K; Miyamoto Y; Hiraike H; Hiraike-Wada O; Nei T; Kawana K; Kuramoto H; Aburatani H; Yano T; Taketani Y
    Br J Cancer; 2009 Jul; 101(1):145-8. PubMed ID: 19491896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
    Shukla S; Maclennan GT; Hartman DJ; Fu P; Resnick MI; Gupta S
    Int J Cancer; 2007 Oct; 121(7):1424-32. PubMed ID: 17551921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations.
    Hafner C; Landthaler M; Vogt T
    Exp Dermatol; 2010 Aug; 19(8):e222-7. PubMed ID: 20557351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
    Stemke-Hale K; Gonzalez-Angulo AM; Lluch A; Neve RM; Kuo WL; Davies M; Carey M; Hu Z; Guan Y; Sahin A; Symmans WF; Pusztai L; Nolden LK; Horlings H; Berns K; Hung MC; van de Vijver MJ; Valero V; Gray JW; Bernards R; Mills GB; Hennessy BT
    Cancer Res; 2008 Aug; 68(15):6084-91. PubMed ID: 18676830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of LKB1 on the PI3K/Akt pathway activation in association with PTEN and PIK3CA in HNC.
    Ekizoglu S; Dogan S; Ulker D; Seven D; Gozen ED; Karaman E; Buyru N
    Clin Otolaryngol; 2015 Dec; 40(6):622-8. PubMed ID: 25850957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung.
    Stjernström A; Karlsson C; Fernandez OJ; Söderkvist P; Karlsson MG; Thunell LK
    Cancer Med; 2014 Apr; 3(2):337-48. PubMed ID: 24500884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.